Current and historical daily PE Ratio for CRISPR Therapeutics AG (
) from 2018 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. CRISPR Therapeutics AG stock (LTS:0VRQ) PE ratio as of Apr 25 2024 is 0.
More Details
CRISPR Therapeutics AG (LTS:0VRQ) PE Ratio (TTM) Chart
CRISPR Therapeutics AG (LTS:0VRQ) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1256
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| CRISPR Therapeutics AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-19 | At Loss |
| 2024-04-22 | At Loss | 2024-02-16 | At Loss |
| 2024-04-19 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-09 | At Loss |
| 2024-04-12 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
| 2024-04-08 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-25 | At Loss |
| 2024-02-26 | At Loss | 2023-12-22 | At Loss |
| 2024-02-23 | At Loss | 2023-12-21 | At Loss |
| 2024-02-22 | At Loss | 2023-12-20 | At Loss |
| 2024-02-21 | At Loss | 2023-12-19 | At Loss |
CRISPR Therapeutics AG (LTS:0VRQ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
CRISPR Therapeutics AG
ISIN : CH0334081137
Share Class Description:
LTS:0VRQ: Ordinary SharesCompare
Compare
Traded in other countries / regions
CRSP.USACRSP.Mexico1CG.Germany0VRQ.UK IPO Date
2018-01-19Description
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers